Last reviewed · How we verify
Conventional steroid regimen
Conventional steroid regimen is a Small molecule drug developed by Centro de Investigación en. Enfermedades Infecciosas, Mexico. It is currently in Phase 1 development. Also known as: CoSt.
A conventional steroid regimen is used in combination with other treatments, such as JNJ-75276617, Fludarabine, and Cytarabine, to study various conditions including Acute Leukemias and Ductal Breast Carcinoma in Situ. The conventional steroid regimen is a component of a treatment approach that involves small molecule interventions, as classified by ChEMBL.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Conventional steroid regimen |
|---|---|
| Also known as | CoSt |
| Sponsor | Centro de Investigación en. Enfermedades Infecciosas, Mexico |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Short-term Steroid Therapy in Patients With P. Jirovecii Pneumonia Due to HIV / AIDS (NA)
- A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab (PHASE3)
- Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma (PHASE3)
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- STeroids and Enhanced Spectrum Antibiotics for the Treatment of Patients in Africa With Refractory Sepsis (PHASE3)
- Linperlisib Combined With Chidamide in Patients With PTCL (PHASE1, PHASE2)
- Conventional Prophylactic Oral Dexamethasone vs Short-course IV Dexamethasone in Paclitaxel Hypersensitivity (PHASE3)
- Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Conventional steroid regimen CI brief — competitive landscape report
- Conventional steroid regimen updates RSS · CI watch RSS
- Centro de Investigación en. Enfermedades Infecciosas, Mexico portfolio CI
Frequently asked questions about Conventional steroid regimen
What is Conventional steroid regimen?
Who makes Conventional steroid regimen?
Is Conventional steroid regimen also known as anything else?
What development phase is Conventional steroid regimen in?
Related
- Manufacturer: Centro de Investigación en. Enfermedades Infecciosas, Mexico — full pipeline
- Also known as: CoSt
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing